Antibodies and T cells against synthetic peptides of the C-terminal domain (H(c)) of botulinum neurotoxin type A and their cross-reaction with H(c)

Immunology Letters

Volumn 60, Issue 1, 1998, Pages 7-12

  Oshima, Minako ^a   Middlebrook, John L ^b   Atassi, M Zouhair ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Life Science Division   (United States)

Author keywords

Antibodies; Botulinum neurotoxin; Epitopes; Synthetic peptides; T cells

Indexed keywords

BACTERIAL VACCINE; BOTULINUM TOXIN A; CROSS REACTING ANTIBODY; EPITOPE; NEUROTOXIN; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BOTULISM; CLOSTRIDIUM BOTULINUM; CROSS REACTION; IMMUNIZATION; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MOUSE; NEUROTOXICITY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; BOTULINUM TOXIN TYPE A; CELL DIVISION; CROSS REACTIONS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0031939333     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(97)00124-7     Document Type: Article

References (21)

1. [1] C. Lamanna, Science 130 (1959) 763-772.
2. [2] J.L. Middlebrook, J. Toxicol. Toxin Rev. 5 (1986) 177-190.
3. [3] K. Oguma, Y. Fujinaga, K. Inoue, Microbiol. Immunol. 39 (1995) 161-168.
4. [4] S. Kozaki, A. Miki, Y. Kamata, J. Ogasawara, G. Sakaguchi, Infect. Immun. 57 (1989) 2634-2639.
5. [5] C.C. Shone, P. Hambleton, J. Melling, Eur. J. Biochem. 151 (1985) 75-82.
6. [6] M.A. Clayton, J.M. Clayton, D.R. Brown, J.L. Middlebrook, Infect. Immun. 63 (1995) 2738-2742.
7. [7] J.L. Middlebrook, Adv. Exp. Med. Biol. 383 (1995) 93-98.
8. [8] M. Oshima, M. Hayakari, J.L. Middlebrook, M.Z. Atassi, Mol. Immunol. (1997) in press.
9. [9] M.Z. Atassi, B.Z. Dolimbek, M. Hayakari, J.L. Middlebrook, B. Whitney, M. Oshima, J. Protein Chem. 15 (1996) 691-700.
10. [10] G.S. Bixler, M.Z. Atassi, Eur. J. Immunol. 15 (1985) 917-922.
11. [11] G.S. Bixler, T. Yoshida, M.Z. Atassi, Immunology 56 (1985) 103-112.
12. [12] V. Bhardwaj, V. Kumar, I.S. Grewal, T. Dao, P.V. Lehmann, H.M. Geysen, E.E. Sercarz, J. Immunol. 152 (1994) 3711-3719.
13. [13] S.J. Brett, K.B. Cease, J.A. Berzofsky, J. Exp. Med. 168 (1988) 357-373.
14. [14] G.F. Hoyne, M.G. Callow, M.-C. Kuo, W.R. Thomas, Immunology 78 (1993) 58-64.
15. [15] M.Z. Atassi, S. Yokota, S.S. Twining, H. Lehmann, C.S. David, Mol. Immunol. 18 (1981) 961-967.
16. [16] F. Celada, E.E. Sercarz, Vaccine 6 (1988) 94-98.
17. [17] J.S. Rosenberg, M. Oshima, M.Z. Atassi, J. Immunol. 157 (1996) 3192-3199.
18. [18] A.I.P.M. DeKroon, H.M. McConnel, Proc. Natl. Acad. Sci. USA 90 (1993) 8797-8801.
19. [19] M.-H.L. Feng, M.-Z. Lai, Eur. J. Immunol. 24 (1994) 355-361.
20. [20] B.Z. Dolimbek, M.Z. Atassi, Mol. Immunol. 33 (1996) 681-689.
21. [21] P. Panina-Bordignon, A. Tan, A. Termijtelen, S. Demotz, G. Corradin, A. Lanzavecchia, Eur. J. Immunol. 19 (1989) 2237-2242.